Hydrocortisone 2.5% Rx
Generic Name and Formulations:
Hydrocortisone 2.5%; crm; oint, lot.
Various generic manufacturers
Indications for Hydrocortisone 2.5%:
Adults and Children:
Apply thin film 2–4 times daily.
Do not use superpotent forms on face, groin, or axillae. Exclude viral disease (eg, chickenpox, measles).
Treat infection if present; discontinue if infection persists or worsens. Do not use near eyes, or on diaper dermatitis or pre-existing skin atrophy. Do not use fluorinated steroids longer than 1 week on the face. Avoid abrupt cessation in chronic use. Systemic absorption increased by broken or inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Occlude only if necessary; do not occlude higher potency products. Monitor adrenal function in children if a high potency product or occlusion is used, and in adults if more than 50g weekly of a high potency product is used. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Use lowest effective dose and potency (esp. in children). Use caution if applying to face or body folds. Do not use continuously or for prophylaxis. Foams are flammable. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, stinging, pruritus, erythema, skin atrophy, striae, miliaria, secondary infections, hypopigmentation, folliculitis, hypertrichosis, acneiform eruptions, dermal cracking and fissuring, telangiectasia, contact dermatitis, other local effects, immunosuppression, masks infections, HPA axis suppression (esp. in children).
Formerly known under the brand name Cortaid, Hytone.
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Opioids: Clinician Concern and Prescribing Practices
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- CDC: 8.8% of Individuals in the United States Uninsured in First Half of 2018
- Patient Experiences Shed Light on Diagnostic Errors
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Wikipedia in Medical Education: An Educator's Guide to Crowdsourcing